Affordable Access

deepdyve-link
Publisher Website

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

Authors
  • Boerrigter, Emmy1
  • Benoist, Guillemette E.1
  • van Oort, Inge M.2
  • Verhaegh, Gerald W.2
  • van Hooij, Onno2
  • Groen, Levi2
  • Smit, Frank3
  • Oving, Irma M.4
  • de Mol, Pieter5
  • Smilde, Tineke J.6
  • Somford, Diederik M.7
  • Mehra, Niven8
  • Schalken, Jack A.2
  • van Erp, Nielka P.1
  • 1 Radboud Institute for Health Sciences, the Netherlands , (Netherlands)
  • 2 Radboud Institute for Molecular Life Sciences, the Netherlands , (Netherlands)
  • 3 MDxHealth, the Netherlands , (Netherlands)
  • 4 Ziekenhuisgroep Twente, the Netherlands , (Netherlands)
  • 5 Gelderse Vallei Hospital, the Netherlands , (Netherlands)
  • 6 Jeroen Bosch Hospital, the Netherlands , (Netherlands)
  • 7 Canisius Wilhelmina Hospital, the Netherlands , (Netherlands)
  • 8 Radboud University Medical Center, the Netherlands , (Netherlands)
Type
Published Article
Journal
Molecular Oncology
Publisher
Wiley (John Wiley & Sons)
Publication Date
May 29, 2021
Volume
15
Issue
9
Pages
2453–2465
Identifiers
DOI: 10.1002/1878-0261.12933
PMID: 33650292
PMCID: PMC8410566
Source
PubMed Central
Keywords
Disciplines
  • Research Articles
License
Unknown
External links

Abstract

Circulating RNAs extracted from liquid biopsies represent a promising source of cancer‐ and therapy‐related biomarkers. KLK3 mRNA detection in whole blood is an independent prognostic marker for progression‐free survival in mCRPC patients. KLK3 mRNA levels probably correspond to the number of circulating tumor cells. Therefore, KLK3 detection may be a potential biomarker to monitor treatment response but prospective clinical validation is needed.

Report this publication

Statistics

Seen <100 times